Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Senior Appointment

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') SENIOR APPOINTMENT: GEOMERICS LTD ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-basedindustry, is pleased to announce the appointment of Gary Lewis as ChiefExecutive Officer at its Progeny(R) venture company Geomerics Ltd. Mr. Lewis (aged 44) joins Geomerics following eight years at Take-Two (NASDAQ:TTWO), a leading worldwide publisher, developer and distributor of interactiveentertainment software and accessories. Gary most recently held the position ofGlobal Chief Operating Officer, based in New York and was previously Presidentof International Operations for three years, operating out of the UK. Founded in 2005, Geomerics has secured intellectual property in the field ofgeometric algebra, a powerful new form of mathematics that vastly simplifiescomplex geometric calculations. Geometric algebra has its origins in the ratheresoteric academic discipline of theoretical cosmology, but it has now beendeveloped for application in computer graphics. Geomerics' technology provides a major step-change improvement over thecompetition, and is set to revolutionise the market. Overall the market forcomputer games is currently worth more than $30bn and growing rapidly, and themarket for graphics within these games is worth over $1.8bn per year. Since itsestablishment, Geomerics has developed a suite of impressive demonstrationswhich have attracted considerable interest from potential customers. Following Gary's appointment, founder Dr Chris Doran will move from CEO to ChiefOperating Officer where he will focus on the development of Geomerics' productsand markets. Commenting on his appointment, Gary Lewis said: "I am delighted to be joining Geomerics. I have been extremely impressed byGeomerics' product pipeline and look forward to putting the substantialadvantages of the technology into the hands of developers and publishers of nextgeneration titles. I am particularly excited by the launch of our first product,a real-time Radiosity lighting solution." Dr Chris Doran, COO of Geomerics added: "Gary is an industry heavyweight and will be a valuable asset to us. Geomerics'product pipeline is progressing quickly and we are confident it has the capacityto greatly impact this industry in the near future. Gary's experience will beinvaluable in our drive towards commercialisation. We are truly excited to havehim on board." Andrew Newland, Chief Executive of ANGLE plc said: "Gary Lewis is one of the leading executives in computer games industry. Hiscommercial experience and the outstanding network of contacts he has developedwhilst at Take Two will be a major advantage to Geomerics in securing commercialdeals to exploit its technology platform. Gary's recruitment is a coup forGeomerics and a vote of confidence in the business." For further information:ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveJohn Holden, Director - Ventures Development Geomerics Ltd 01223 370030Dr Chris Doran, Founder & Chief Operating Officer Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Furtherinformation can be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.